Cite
HARVARD Citation
Mosenzon, O. et al. (2019). Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet. 7 (7), pp. 515-527. [Online].